…and without germline BRCA mutations. In a randomized, double-blind, phase III trial of over 550 women both with and without germline BRCA mutations, researchers found that patients receiving niraparib once…
…BRCA2. Learn more. Of the 1,915 patients surveyed, eighteen percent carried a gene mutation known to be associated with ovarian cancer, such as BRCA1 and BRCA2. Learn more. 19 19…
…her mother’s negative BRCA gene mutations test result. However, prompted by her doctors, she took an at-home saliva test, and discovered that she carries a BRCA 2 mutation inherited from…
…research. SA: Women with ovarian cancers that result from an inherited mutation in the BRCA gene show excellent response to a drug called a PARP inhibitor. The drug specifically kills…
…genetic makeup – a BRCA gene mutation. Dawn and Jamie A Tough Decision Her sister and mother had it, and both had been diagnosed with cancer – first her mother…
…(which looks for mutations in many genes), identifies more people with cancer risk related gene mutations than screening for BRCA1 and 2 alone. Importantly, identifying these additional gene mutations provides…
…tumor cells in laboratory cell lines and tumor models with BRCA1 or BRCA2 genetic mutations. Read on to discover how it has been found to be effective even in tumors that have…
…cancers. Specifically, we are targeting the cell’s repair mechanism, which mends breaks in the DNA and corrects mistakes. In cancer cells, defects in the BRCA1 or BRCA2 genes cause one…
…in the DNA and corrects mistakes. In cancer cells, defects in the BRCA1 or BRCA2 genes cause one of the repair mechanisms, or pathways, to lose function. In the absence…
…to 70% in women with BRCA 1 or 2 positive, advanced stage epithelial ovarian, fallopian tube, and primary peritoneal cancers. Those included in the study received cytoreductive surgery and had…
…a mouse model of BRCA1-deficient ovarian cancer. Combining a PARP-inhibitor with immune therapy resulted in tumor rejection and long-term survival in a mouse model of BRCA1-deficient ovarian cancer. 19 19…
…cancer patients without BRCA mutations. The research was funded in part by an OCRFA grant to Rugang, Zhang, PhD. PARP inhibitors have already been approved to treat BRCA-mutant ovarian cancers,…
Get email updates about research news, action alerts, and ways to join the fight.
